It's interesting that during 2011 the big dips happened after AEN raised several million dollars subsequent to 3 private offerings, to people with vested interests in reaZin's positive results, because they saw it first hand in their mothers. All the new money was at 60¢ and $1.10¢ above where it is now.
I can see that some people saw this as panic dilution, and that's why the stock ran downward.
As for Fibromyalgia ... [Effirma (flupirtine)] ... my sister-in-law has it, and finds no drug to be effective. So I have a two pronged interest in seeing this come to market. Not only may she benefit; Adeona stands to earn some windfall profits when it does, and on an ongoing basis.
Adeona entered into a Sublicense Agreement with Sweden-based Meda AB, to develop flupirtine for fibromyalgia. Under the terms of the agreement, Meda will assume all future development costs for the commercialization of flupirtine for fibromyalgia. Adeona received an up-front payment of $2.5 million and is entitled to milestone payments of $5 million upon filing of a New Drug Application with the FDA for flupirtine for fibromyalgia and $10 million upon marketing approval. Adeona is also entitled to receive royalties of 7% of net sales of flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the Territory.
News 
Market Data 
Discover 
